Madrigal Pharmaceuticals Inc

NASDAQ:MDGLUnited States

Rezdiffra may cause serious side effects, including:
-- liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), pain or tenderness in the upper middle or upper right area of your stomach (abdomen). -- gallbladder problems. Gallbladder problems such as gallstones, inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with NASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

03:08 AM EDT, 05/17/2024 (MT Newswires) -- Fred B Craves, Director, on May 14, 2024, sold 22,489 shares in Madrigal Pharmaceuticals (MDGL) for $4,787,404. Following the Form 4 filing with the SEC, Craves has control over a total of 489,685 shares of...